Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Initiates Phase 2 Clinical Trial for Treatment of Post Traumatic Stress Disorder

PRWeb - May 2012

Nanotherapeutics is assessing the safety of its drug (PRX-3140) for treating PTSD - post traumatic stress disorder. About 300,000 veterans of the recent wars are estimated to be affected by PTSD or major depression.

Full Article

Copyright 2017 NANOTHERAPEUTICS, INC.  All rights reserved.